REMEGEN (09995) enters into a licensing agreement with CanSino Biologics China.

REMEGEN (09995) announced on August 18, 2025 that the company has entered into a licensing agreement with CanSino Biologics Inc. (CanSino China) for the compensated licensing of RC28-E injection, a product with independent intellectual property rights. CanSino China will obtain exclusive development, production, and commercialization rights in the Greater China region (including China, Hong Kong, Macau, and Taiwan), as well as in South Korea, Thailand, Vietnam, Singapore, the Philippines, Indonesia, and Malaysia (licensed territory), while the company will retain global exclusive rights for RC28-E outside of the licensed territory. Under the licensing agreement and subject to its terms and conditions, the company will receive (i) a non-refundable and non-deductible upfront payment of 250 million RMB from CanSino China; (ii) milestone payments for development and regulatory approval up to a maximum of 520 million RMB; and (iii) sales milestone payments up to a maximum of 525 million RMB. In addition, the company will also receive high single to double-digit percentage sales royalties based on product sales within the licensed territory. The licensing agreement will be effective starting from August 18, 2025, and will remain valid unless terminated early in accordance with the agreement. The signing of the licensing agreement will accelerate the market access and patient coverage for RC28-E, significantly shorten the commercialization cycle, and provide innovative and efficient solutions for the treatment of retinal diseases. RC28-E injection is a VEGF/FGF dual-target fusion protein drug developed independently by the company for neovascular eye diseases. On May 7, 2025, the phase II clinical trial results of RC28-E for treating diabetic macular edema (DME) were presented orally at the Association for Research in Vision and Ophthalmology (ARVO 2025) annual meeting in the United States. The study demonstrated excellent results in improving best-corrected visual acuity (BCVA) in DME patients, reducing central subfield thickness (CST) of the macula, and effectively relieving macular edema. In 2023, the company initiated phase III clinical trials for the use of RC28-E injection in treating wet age-related macular degeneration (wAMD) and diabetic macular edema.